Does mofetil mycophenolate (MMF) delay hepatitis C recurrence in liver transplant patients?

被引：0
|
作者：
Fasola, CG [1 ]
Netto, GJ [1 ]
Jennings, LW [1 ]
Gonwa, TA [1 ]
Goldstein, RM [1 ]
Levy, MF [1 ]
Molmenti, EP [1 ]
Klintmalm, GB [1 ]
机构：
[1] Baylor Univ, Med Ctr, Transplant Serv, Dallas, TX USA
来源：
TRANSPLANTATION | 2000年 / 69卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
33
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [1] Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Sanchez, EQ
    Molmenti, EM
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    [J]. HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [2] Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1563 - 1564
  • [3] Natural history of recurrence of hepatitis C (HEP CR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS).
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    [J]. HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [4] Mycophenolate mofetil (MMF) in pediatric liver transplant recipients
    Dhawan, A
    Lewis, PN
    Heaton, ND
    Baker, AJ
    Rela, M
    Hadzic, N
    Srinivasan, P
    MieliVergani, G
    [J]. HEPATOLOGY, 1997, 26 (04) : 1487 - 1487
  • [5] Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1561 - 1562
  • [6] Pharmacokinetics (PK) of intravenous mycophenolate mofetil (MMF) in liver transplant patients.
    Hebert, MF
    Chang, T
    Linna, TJ
    Hale, MD
    Roberts, JP
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI101 - PI101
  • [7] Hepatitis C recurrence (HCVR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS): A long-term follow up
    Fasola, CG
    Netto, GJ
    Sanchez, EQ
    Chinnakotla, S
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 356 - 356
  • [8] Initial clinical evidence that mofetil mycophenolate (MMF) antiviral effects may delay the recurrence of hepatitis C (HEP C) and reduce the incidence of CMB infection in HEP C liver transplant recipients (OLT).
    Fasola, CG
    Netto, G
    Jennings, LW
    Jung, GJ
    Marubashi, S
    Sanchez, EQ
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Klintmalm, GB
    [J]. HEPATOLOGY, 2000, 32 (04) : 290A - 290A
  • [9] Severe anemia with Sofosbuvir based therapy for Hepatitis C (HCV) recurrence post Liver transplantation on mycophenolate mofetil (MMF)
    Elsiesy, Hussien
    Ajlan, Aziza A.
    Aljedai, Ahmed
    Alarieh, Rania
    Al-Hamoudi, Waleed K.
    Alkortas, Delal
    Al Sebayel, Mohammed
    Broering, Dieter C.
    Abaalkhail, Faisal A.
    [J]. HEPATOLOGY, 2014, 60 : 702A - 703A
  • [10] Evaluation of the role of mofetil mycophenolate (MMF) in delaying progression of hepatitis C (HepC) recurrence following orthotopic liver transplantation (OLTX)
    Netto, G
    Fasola, C
    Parker, C
    Mattison, TL
    Jennings, J
    Molmenti, E
    Levy, M
    Goldstein, R
    Klintmalm, G
    [J]. LABORATORY INVESTIGATION, 2001, 81 (01) : 201A - 201A
12345